Can You Microdose Testosterone? What the Science Says

Microdosing testosterone is not a single defined medical protocol but a loosely used term for taking testosterone at doses well below what standard guidelines recommend for full hormone replacement. It is a real practice with growing clinical use, particularly in gender-affirming care for non-binary individuals, and it produces measurable hormonal and physical effects. But the word “microdose” can mislead: even small amounts of exogenous testosterone trigger the same feedback loop in your endocrine system that larger doses do, which means some of the risks people hope to avoid by going low still apply.

What “Microdosing” Actually Means in Practice

There is no universally agreed-upon definition of a testosterone microdose. In clinical settings, the term usually refers to doses that aim to produce slow, partial masculinization rather than the rapid, complete changes associated with standard testosterone replacement therapy (TRT). Standard TRT for transgender men or hypogonadal cisgender men typically targets serum testosterone in the normal adult male range. Microdosing aims for something lower, often keeping levels in the high-female or low-male range, or simply starting at a fraction of the conventional dose and staying there.

A retrospective audit of non-binary individuals on transdermal testosterone found that most people who started on low doses continued at doses below guideline recommendations after six to twelve months of treatment, suggesting that for many, a low dose was the intended destination rather than just a starting point.¹ In broader gender-affirming care, non-binary individuals were more likely to receive tailored hormone therapy compared to binary transgender people, with about 11% on a tailored regimen versus roughly 5% of binary trans patients.²

Outside gender-affirming care, “microdosing testosterone” shows up in wellness and anti-aging communities, in women seeking libido or energy improvements, and in sports doping. Each of these contexts uses different doses, different delivery methods, and carries different risk profiles. The science behind each is worth pulling apart separately.

Your Endocrine System Responds to Any Exogenous Testosterone

One of the most important things to understand about taking testosterone at any dose is what it does to your body’s own production. Your brain monitors circulating testosterone levels and adjusts its signaling accordingly. When exogenous testosterone enters your bloodstream, your pituitary gland dials back its output of the hormones that stimulate your testes (or ovaries) to produce testosterone naturally. This negative feedback loop is dose-dependent, meaning larger doses suppress your natural production more, but even modest doses trigger it.³

In a study of normal men given weekly testosterone injections, a relatively low dose of 50 mg per week cut gonadotropin levels and sperm counts roughly in half compared to placebo.³ That is not a trivial suppression. The practical takeaway is that a “microdose” does not sidestep your body’s hormonal feedback. It turns the dial down rather than off, but the dial still moves.

Delivery Method Shapes What a Low Dose Actually Does

How you take testosterone matters as much as how much you take, especially at low doses. The main options are injectable esters (intramuscular or subcutaneous), transdermal gels or patches, and subcutaneous pellets. Each creates a different pharmacokinetic profile, meaning the peaks, troughs, and overall stability of testosterone in your blood can vary considerably.

Transdermal gels are popular for microdosing because they produce relatively steady serum levels. In hypogonadal men, daily gel application raised testosterone into the normal range within a day and maintained stable levels over six months.⁴ One practical detail: applying gel to the abdomen produced roughly 30-40% lower bioavailability than applying it to the upper arms or shoulders, which means application site alone can substantially change your effective dose.⁵

Subcutaneous injections offer another route with a smoother absorption curve compared to traditional intramuscular shots. A pharmacokinetic study comparing subcutaneous and intramuscular injection of testosterone undecanoate found that the subcutaneous route peaked later (about eight days versus three) but reached similar peak concentrations.⁶ Subcutaneous injection generally results in more stable serum levels because lymphatic flow in the fat layer under the skin fluctuates less with physical activity than deeper muscular blood flow does.⁷

This matters for microdosing because peak-and-trough swings are a known driver of certain side effects. Short-acting intramuscular injections of testosterone cypionate or enanthate produce the biggest swings and carry the highest rates of erythrocytosis, a condition where red blood cell counts climb too high. That incidence approaches 40% with standard IM injections. Formulations that keep levels stable, like gels, patches, and subcutaneous routes, produce much lower rates of erythrocytosis.⁸ If you are microdosing and want to minimize side effects, your choice of delivery method is arguably as important as the dose itself.

Body Composition on Low Doses

One of the draws of microdosing is the hope that small amounts of testosterone can shift body composition, adding lean mass and reducing body fat, without producing the full range of androgenic changes. There is evidence that this works to a degree. A long-term study comparing low-dose and high-dose testosterone therapy in trans men found that both groups lost body fat and gained lean mass during the first year. The high-dose group gained more lean mass initially, but over the longer term the differences between groups narrowed.⁹ The researchers concluded that adequate muscular development was achievable through low-dose therapy, though you get there more slowly.

For people looking at microdosing as a body-composition tool without a medical need for testosterone, the tradeoff is real: you are still shutting down part of your natural hormone production, accepting some risk of side effects, and the lean-mass gains, while present, are modest compared to what comes from strength training alone. The effect is not nothing, but it is also not the dramatic recomposition some online communities promise.

Fertility Is Not Spared

A persistent misconception is that microdosing testosterone will not affect fertility because the dose is too small. The evidence says otherwise. Exogenous testosterone, even at modest levels, suppresses the signals that drive sperm production. Testosterone levels inside the testes need to be extremely high, far above what circulates in your blood, to maintain normal sperm production. External testosterone collapses that internal gradient.¹⁰ The suppression is dose-dependent but not linear in a way that gives you a safe floor. Even the 50 mg weekly dose mentioned earlier, which many would consider a low dose, halved sperm production in study participants.³

This is not necessarily permanent. After stopping testosterone, reproductive hormone levels do recover, but the timeline can be long. A study of men who stopped two years of injectable testosterone undecanoate treatment found that full hormonal recovery took about fifteen months.¹¹ Factors that predict faster recovery include shorter cycle duration and using only a single compound. Using multiple anabolic agents or staying on for more than six months both lowered the odds of normalization.¹² Anyone considering microdosing who might want biological children should take this seriously, because the fertility impact is one area where “low dose” does not reliably mean “low risk.”

Low-Dose Testosterone in Women

Women represent a separate context for low-dose testosterone use. The doses studied in women are genuinely tiny compared to male TRT, typically in the range of 150 to 300 micrograms per day via transdermal patch, about a hundredth of what a man on standard TRT receives. The main studied indication is low sexual desire after menopause.

A large randomized trial in postmenopausal women not taking estrogen found that 300 micrograms per day of transdermal testosterone increased the frequency of satisfying sexual episodes by about two per month more than placebo, with significant improvements in desire and reductions in distress. The lower 150 microgram dose improved desire modestly but did not reach significance for the primary outcome.¹³ A systematic review of these trials confirmed that testosterone therapy improves sexual function in postmenopausal women but also noted decreases in HDL cholesterol and uncertain long-term safety.¹⁴

Side effects in women at these low doses are generally mild. Hirsutism, meaning unwanted hair growth, appears in roughly 15-20% of women on physiological androgen replacement, and more serious virilization is rare at these levels.¹⁵ Still, a Brazilian endocrinology society position statement captured the honest state of the field: testosterone appears to help desire in women with sexual dysfunction, but the effect is small, long-term safety data are lacking, and the evidence is not strong enough for a broad recommendation.¹⁶

Mood, Cognition, and the Placebo Problem

Many people who microdose testosterone report improved mood, sharper thinking, and better energy. Some clinical evidence supports this, but the picture is nuanced. A pilot study of peri- and postmenopausal women on transdermal testosterone found that mood and cognitive symptoms both improved, with mood improving somewhat more than cognition.¹⁷ A systematic review of testosterone therapy in men found that it improved depressive symptoms in treatment-resistant depression and enhanced verbal memory and visuospatial processing in older or hypogonadal men.¹⁸ A separate trial in men with mild cognitive impairment and low testosterone found modest improvements in verbal memory and depression, but no changes in other cognitive measures or quality of life.¹⁹

The challenge is that expectancy effects with testosterone are powerful. A randomized trial in men with erectile dysfunction found no significant differences in mood or well-being between the testosterone and placebo groups.²⁰ People who believe they are taking testosterone often report feeling better regardless of whether they are, which complicates the self-reports that dominate online microdosing communities. The benefits appear most reliable in people who are genuinely starting from low levels, whether due to menopause, aging, or clinical hypogonadism. For someone with normal testosterone levels, the mood-enhancing effects of a microdose are likely modest at best and hard to separate from placebo.

Cardiovascular and Lipid Concerns at Low Doses

One area where dose may genuinely matter for safety is cardiovascular risk. A review of testosterone therapy in postmenopausal women found that testosterone alone significantly decreased HDL (the “good” cholesterol) while LDL stayed unchanged. The review also noted that the correlation between high-dose testosterone therapy and atherosclerosis may not apply to low-dose therapy, suggesting that the cardiovascular risks of microdosing are likely smaller than those of full TRT, though not zero.²¹ Monitoring bloodwork, particularly hematocrit, lipid panels, and liver function, remains standard clinical practice even at low doses.

Bone density is another area where testosterone provides a documented benefit. Studies support that testosterone replacement improves bone mineral density in hypogonadal men with osteopenia or osteoporosis, though not all studies agree on the magnitude.²² Whether a microdose provides the same bone-protective effect as a standard dose is an open question, since most bone-density studies used standard replacement protocols.

Anti-Doping Detection of Microdoses

In competitive sports, “microdosing testosterone” means something specific: using the smallest effective dose to gain a performance edge while staying below detection thresholds. Anti-doping science has been adapting. A study of a single application of 100 mg testosterone gel to men found that the Athlete Biological Passport (ABP) successfully flagged all eight subjects through longitudinal monitoring of urine biomarkers, though isotope ratio mass spectrometry (IRMS) confirmed only two of five subjects tested as definitively positive.²³

More recently, a study tested an even smaller single microdose in healthy volunteers and found that IRMS analysis was positive in all samples analyzed, even when the standard testosterone-to-epitestosterone ratio stayed below the conventional suspicious threshold.²⁴ In women, detection is harder. A study administering 12.5 mg of transdermal testosterone gel daily for seven days to healthy females found that urine and serum markers had a detection window of only two to four days. Combining steroid markers with hematological measures like reticulocyte counts improved accuracy to about 93% correct classification, but with some false negatives.²⁵ The arms race between microdosing athletes and anti-doping labs is ongoing, with detection methods steadily improving but imperfect at the lowest doses.

The Risks of Going It Alone

A significant portion of testosterone microdosing happens outside medical supervision, using products sourced from compounding pharmacies, online clinics with minimal oversight, or underground markets. The quality problem with non-pharmaceutical testosterone products is well documented. A systematic review and meta-analysis of black-market anabolic steroids estimated that about 36% of products were counterfeit and another 37% were substandard, meaning they contained the wrong dose, the wrong ingredient, or no active ingredient at all.²⁶

A laboratory analysis of underground market products found that about 64% had concentrations more than 20% above or below what was listed on the label, about 57% failed purity tests, and roughly a fifth showed contamination with heavy metals.²⁷ A more recent harm-reduction study that analyzed user-submitted samples using mass spectrometry found that about 20% contained a different compound than expected, and roughly a third had concentrations that were too high or too low.²⁸

If you are trying to take a precise low dose and the product contains twice what the label says, you are not microdosing. You are taking a standard or supraphysiological dose without knowing it. This is one of the most concrete dangers of unsupervised microdosing: the dose precision that the strategy depends on simply does not exist without pharmaceutical-grade products and clinical monitoring.

What Happens When You Stop

People sometimes assume that stopping a microdose will be easier than stopping a standard dose, and to some extent this is true, but the recovery still takes time. After two years of testosterone undecanoate injections, full recovery of reproductive hormones took about fifteen months from the last injection.¹¹ Shorter cycles and single-compound use predicted faster recovery. Men who used post-cycle therapy recovered about twice as fast as those who did not when they stopped within three months, but the benefit disappeared for those who had stopped more than three months prior.¹²

The variable nobody can predict for you in advance is how your individual hypothalamic-pituitary-gonadal axis will respond. Some men bounce back in weeks; others are biochemically suppressed for over a year. The lower the dose and the shorter the duration, the better the odds of faster recovery, but there are no guarantees. Anyone microdosing without medical supervision who plans to stop eventually should be aware that the off-ramp is not instantaneous.

Where the Evidence Lands on “Alternatives” to Exogenous Testosterone

Some of the appeal of microdosing reflects a real dissatisfaction with the all-or-nothing framing of conventional testosterone therapy. For people who want modest hormonal shifts rather than full replacement, there are medications that work differently. Rather than adding external testosterone, certain drugs modulate the body’s own signaling to increase endogenous production. These are considered off-label for testosterone replacement and work through the hypothalamic-gonadal axis to boost the body’s own output, which can increase testosterone levels without the same degree of suppression that exogenous testosterone causes.²⁹ These approaches do not suppress sperm production the way exogenous testosterone does, which makes them relevant for anyone concerned about fertility.

For cisgender men with borderline-low testosterone, this distinction matters. Taking even a small dose of exogenous testosterone shuts down endogenous production proportionally, which is counterproductive if you are trying to preserve your natural hormonal function. The off-label alternatives have their own limitations, including less robust evidence and off-label legal status, but they represent a fundamentally different approach to the same goal that many microdosers are chasing: a modest hormonal boost without full commitment to replacement therapy.

1
PubMed Central. Initiation and Maintenance of Low-Dose Transdermal Testosterone in Non-Binary Individuals: A Retrospective Audit
2
PubMed Central. Tailored Gender-Affirming Hormone Treatment in Nonbinary Transgender Individuals: A Retrospective Study in a Referral Center Cohort
3
The Journal of Clinical Endocrinology & Metabolism. Effects of Chronic Testosterone Administration in Normal Men: Safety and Efficacy of High Dosage Testosterone and Parallel Dose-Dependent Suppression of Luteinizing Hormone, Follicle-Stimulating Hormone, and Sperm Production
4
The Journal of Clinical Endocrinology & Metabolism. Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men
5
PubMed. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism
6
PubMed Central. Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate
7
The Journal of Clinical Endocrinology & Metabolism. Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option
8
PubMed Central. Erythrocytosis Following Testosterone Therapy
9
PubMed. Trans men can achieve adequate muscular development through low-dose testosterone therapy: A long-term study on body composition changes
10
PubMed Central. Exogenous testosterone: a preventable cause of male infertility
11
PubMed. Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections
12
European Journal of Endocrinology. Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study
13
PubMed. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen
14
PubMed. A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women
15
Mayo Clinic Proceedings. Safety and Adverse Effects of Androgens: How to Counsel Patients
16
PubMed Central. Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism
17
PubMed Central. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study
18
PubMed Central. Psychiatric and Cognitive Effects of Testosterone Therapy in Adult Men: A Systematic Review of Clinical Evidence and Mechanistic Insights
19
PubMed Central. Testosterone treatment of men with mild cognitive impairment and low testosterone levels
20
PubMed Central. The Effect of Testosterone on Mood and Well-being in Men with Erectile Dysfunction in a Randomized, Placebo-Controlled Trial
21
Journal of the Endocrine Society. The Impact of Testosterone Therapy on Cardiovascular Risk Among Postmenopausal Women
22
PubMed Central. Testosterone and Bone Health in Men: A Narrative Review
23
PubMed. Sensitivity of doping biomarkers after administration of a single dose testosterone gel
24
PubMed Central. Detection of a Single Microdose of Testosterone and Recombinant EPO in Healthy Volunteers
25
PubMed. Detection of testosterone microdosing in healthy females
26
PubMed Central. Fake anabolic androgenic steroids on the black market – a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature
27
Asian Journal of Research in Medical and Pharmaceutical Sciences. Anabolic Androgenic Steroids from Underground Market: drug Quality and Implications for Research
28
PubMed Central. Anabolic-androgenic steroid testing as a tool for consumer engagement and harm reduction: a sequential explanatory mixed-method study
29
PubMed Central. Off label therapies for testosterone replacement